OR4M1 and type 2 diabetes mellitus: If we consider that the levels of Olfr734 in the liver of DIO mice and T2DM patients are higher than those in the controls, the development of a specific pharmacological antagonist/inverse agonist for Olfr734 or another system by which the expression of the Olfr734 gene could be genetically inhibited specifically in the liver in a safe and effective manner without side effects could be a priori a conceivable option.